Altimmune (NASDAQ:ALT) Shares Up 4.9% – Should You Buy?

Altimmune, Inc. (NASDAQ:ALT) shares were up 4.9% during trading on Friday . The stock traded as high as $9.02 and last traded at $9.01. Approximately 1,826,223 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 3,833,614 shares. The stock had previously closed at $8.59.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALT. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Trading Up 4.2 %

The company has a market capitalization of $636.57 million, a price-to-earnings ratio of -5.55 and a beta of 0.15. The stock’s 50 day moving average price is $7.65 and its 200 day moving average price is $7.05.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same quarter in the prior year, the business earned ($0.39) earnings per share. On average, research analysts expect that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALT. Larson Financial Group LLC bought a new position in Altimmune during the third quarter worth $31,000. Horizon Wealth Management LLC acquired a new position in Altimmune in the 2nd quarter valued at about $66,000. PFG Investments LLC bought a new position in Altimmune in the 2nd quarter valued at about $67,000. Principal Financial Group Inc. acquired a new stake in Altimmune during the second quarter worth approximately $70,000. Finally, Verus Capital Partners LLC bought a new stake in shares of Altimmune during the second quarter worth approximately $82,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.